Navigation Links
HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy

The disease burden of diabetes continues to grow and currently affects more that 18 million Americans and their families. These data emphasize a need for alternative diabetes therapies with earlier more physiologic use of insulin.//

The delivery of insulin by the lung may provide an attractive alternative for many patients with diabetes. However, alternative insulin delivery systems must meet certain pharmacokinetic and glucodynamic requirements to reach maximum utility. Specifically, the dose-response characteristics of inhaled insulin should be similar to those of injectable insulins, like human regular insulin or fast-acting insulin analogs such as insulin lispro. A recent study, published in the October issue of Diabetes Care, evaluated the key performance features of a novel inhaled insulin delivery system -- human insulin inhalation powder (HIIP) -- based on AIR particle technology and its relative biopotency compared with subcutaneous (SC) insulin lispro.

The researchers enrolled 20 healthy, nonsmoking, male or female subjects (aged 29.6 years, BMI 23.2 kg/m2) with normal forced vital capacity and forced expiratory volume in an open-label, randomized, seven-period, euglycemic glucose clamp, cross-over trial. Each subject received up to 4 single doses of HIIP and 3 doses of SC lispro from 5 to 18 days apart.

HIIP demonstrated a similar rapid onset but an extended time exposure and a prolonged duration of effect compared with SC lispro. While the time-action profile was longer for HIIP than for SC lispro, both treatments showed rapid initial absorption and similar overall PK exposure and GD effect.

Remarkably, in the current study not a single episode of cough was registered, suggesting an excellent tolerability of the inhaled insulin when formulated by the AIR particle technology. However, the authors warn that this result needs to be confirmed in much larger phase 3 trials. Taken together, these results suppor t the potential utility of inhaled insulin as an alternative to insulin injections. Because the fear of injections is a frequent cause for delaying appropriate care in patients with type 2 diabetes, inhaled insulin may provide a treatment that delivers effective doses of insulin in a less threatening, more satisfying manner, potentially resulting in improved patient compliance and better outcomes.

Related medicine news :

2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. ... that the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior ... award celebrates exceptional special needs providers that excel in synthesizing the areas of ...
(Date:12/1/2015)... ... , ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based ... sale in the United States. Clarity is a Superior Dual Wavelength Platform which ... a single platform that is easy to own and operate. , For over ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - ... to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, ... Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker ... order to date. , The order will be from the China Disabled Persons’ ... Implant System is an effective solution for children and adults suffering from severe ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as having ... Unified Contact Center solutions targeted to the high-end enterprise contact center marketplace. , ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation ... company specializing in oncology, today announced that it has ... company,s pivotal global Phase 3 clinical trial of aldoxorubicin ... was originally estimated to be completed in Q1 2016. The ... conducted under a Special Protocol Assessment from the FDA ...
Breaking Medicine Technology: